Grail Stock

grail.comHealthcareFounded: 2016Funding to Date: $2.02B

GRAIL is a healthcare company specializing in early cancer detection by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to developed a multi-cancer early detection blood test.

Register for Details

For more details on financing and valuation for Grail, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Grail.

Register Today

Grail investors also invested in these private companies

Sequoia Capital China
Canada Pension Plan Investment Board
Hillhouse Capital Group
HuangPu River Capital
PSP Investments

Team

Management Team

Gautam Kollu
Chief Commercial Officer
Jeffrey Huber
Co-Founder & Vice Chairman
Hans Bishop
Chief Executive Officer & Board Member
Kenneth Drazan MD
President
Alex Aravanis Ph.D
Co-Founder, Chief Scientific Officer & Head of Research & Development
Aaron Freidin
Corporate Controller
Matthew Young
Chief Financial Officer & Chief Operating Officer

Board Members

Brook Byers Ph.D
Hans Bishop
Maykin Ho Ph.D
Robert Nelsen
ARCH Venture Partners
Xiangmin Cui Ph.D
Decheng Capital
Catherine Friedman
Kaye Foster
Vikram Bajaj Ph.D
Foresite Capital Management
William Rastetter Ph.D
Hal Barron
Jeffrey Huber
Richard Klausner MD
Illumina

Other companies like Grail in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B

News

The health plan provider will make testing available to its own employees, followed by its approximately 2.2 million commercial members.
Caris said it has already provided materials to Illumina and should not have to indulge a "fishing expedition for irrelevant, highly sensitive details."
The measures are legally binding for both Illumina and Grail, and compliance with them will be monitored by a trustee to be approved by the commission.